{
    "clinical_study": {
        "@rank": "14854", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (broccoli sprout extract)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive broccoli sprout extract PO QD on days 1-14."
            }, 
            {
                "arm_group_label": "Arm II (placebo)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive placebo PO QD on days 1-14."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized pilot trial studies broccoli sprout extract in treating patients with\n      estrogen receptor-positive breast cancer. Broccoli sprout extract contains ingredients that\n      may prevent or slow the growth of certain cancers."
        }, 
        "brief_title": "Broccoli Sprout Extract in Treating Patients With Estrogen Receptor-Positive Breast Cancer", 
        "condition": [
            "Estrogen Receptor-positive Breast Cancer", 
            "Invasive Ductal Breast Carcinoma", 
            "Invasive Lobular Breast Carcinoma", 
            "Stage IA Breast Cancer", 
            "Stage IB Breast Cancer", 
            "Stage II Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Ductal, Breast", 
                "Carcinoma, Lobular"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine whether isothiocyanate-rich broccoli sprout extract (ITC-BSE) modifies\n      biomarkers in breast tumor cells.\n\n      II. To determine whether the intervention alters proliferative and apoptotic markers (Ki-67\n      and cleaved caspase-3).\n\n      III. To determine whether the intervention down-regulates the expression of estrogen\n      receptor (ER).\n\n      IV. To determine whether the intervention induces NAD(P)H dehydrogenase (quinone) 1 (NQO1)\n      expression.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine tolerability of ITC-BSE and compliance in breast cancer patients.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive broccoli sprout extract orally (PO) once daily (QD) on days 1-14.\n\n      ARM II: Patients receive placebo PO QD on days 1-14.\n\n      After completion of study treatment, patients are followed up at 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal (no menstrual cycle in the past 12 months), because menstrual cycle\n             affects baseline expression of biomarkers such as Ki-67\n\n          -  Diagnosed with incident, primary, invasive, ductal or lobular, or other epithelial\n             malignancy, clinical stage I or II, ER positive breast cancer\n\n          -  No neoadjuvant endocrine therapy or chemotherapy\n\n          -  No prior chemotherapy\n\n          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\n\n          -  Willing to avoid cruciferous vegetable intake during the study period (2 weeks)\n\n          -  Demonstrate the ability to swallow and retain oral medication\n\n          -  Subject or legal representative must understand the investigational nature of this\n             study and sign an Independent Ethics Committee/Institutional Review Board approved\n             written informed consent form prior to receiving any study related procedure\n\n        Exclusion Criteria:\n\n          -  Prior invasive breast cancer, prior mastectomy or breast radiation\n\n          -  Current or recent use of reproductive hormone therapy, tamoxifen, aromatase inhibitor\n             or other estrogen inhibitors within the last 90 days, which may affect biomarkers\n\n          -  Intolerance to broccoli/ITC-BSE taste\n\n          -  Current ingestion of broccoli sprout extract, which may confound study results\n\n          -  Current or recent treatment for any malignancy within the last one year, which may\n             affect biomarkers\n\n          -  History of Crohn's disease, celiac sprue or other malabsorption syndrome which may\n             interfere with digestion and absorption of broccoli sprout extract"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753908", 
            "org_study_id": "I 211911", 
            "secondary_id": [
                "NCI-2012-01770", 
                "P30CA016056", 
                "K07CA148888"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (broccoli sprout extract)", 
                "description": "Given PO", 
                "intervention_name": "broccoli sprout extract", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm II (placebo)", 
                "description": "Given PO", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "PLCB"
            }, 
            {
                "arm_group_label": [
                    "Arm I (broccoli sprout extract)", 
                    "Arm II (placebo)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "contact": {
                "email": "ASKRPCI@roswellpark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Jessica Young, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of Broccoli Sprout Extract in Patients With Invasive Breast Cancer", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "Jessica Young, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Appropriate transformation (such log transformation) will be used to achieve normality of the data. Results will be given as the back-transformed geometric means and 95% confidence intervals in order to preserve the units of measurement. Change in immunohistochemistry measures will be calculated for each individual and compared between treatment and placebo groups by use of independent samples t-test. If the normality could not be reached by transformation, Wilcoxon rank-sum test will be used, which considers both the direction and the magnitude of changes.", 
                "measure": "Changes in cell proliferation (Ki-67)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 14 days"
            }, 
            {
                "description": "Appropriate transformation (such log transformation) will be used to achieve normality of the data. Results will be given as the back-transformed geometric means and 95% confidence intervals in order to preserve the units of measurement. Change in immunohistochemistry measures will be calculated for each individual and compared between treatment and placebo groups by use of independent samples t-test. If the normality could not be reached by transformation, Wilcoxon rank-sum test will be used, which considers both the direction and the magnitude of changes.", 
                "measure": "Changes in apoptosis (cleaved caspase 3)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 14 days"
            }, 
            {
                "description": "Appropriate transformation (such log transformation) will be used to achieve normality of the data. Results will be given as the back-transformed geometric means and 95% confidence intervals in order to preserve the units of measurement. Change in immunohistochemistry measures will be calculated for each individual and compared between treatment and placebo groups by use of independent samples t-test. If the normality could not be reached by transformation, Wilcoxon rank-sum test will be used, which considers both the direction and the magnitude of changes.", 
                "measure": "Changes in estrogen receptor expression (ER alpha and ER beta)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 14 days"
            }, 
            {
                "description": "Appropriate transformation (such log transformation) will be used to achieve normality of the data. Results will be given as the back-transformed geometric means and 95% confidence intervals in order to preserve the units of measurement. Change in immunohistochemistry measures will be calculated for each individual and compared between treatment and placebo groups by use of independent samples t-test. If the normality could not be reached by transformation, Wilcoxon rank-sum test will be used, which considers both the direction and the magnitude of changes.", 
                "measure": "Changes in NQO1 expression", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 14 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753908"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}